|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1225 NEW YORK AVE. NW |
Address2 | 8th floor |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 14108-12
|
||||||||
|
6. House ID# 300450000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jane Sheehan |
Date | 10/18/2019 12:51:08 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3222 No Federal Funds for Public Charge Act of 2019 - no Federal funds may be used to carry out the proposed rule of the Department of Homeland Security entitled Inadmissibility on Public Charge Grounds
H.R.1897 MOMMA's Act - Federal efforts with respect to the prevention of maternal mortality
H.R.2115 Public Disclosure of Drug Discounts Act - legislation to provide greater transparency of discounts provided by drug manufacturers.
S.340/H.R.965CREATES - facilitate the timely entry of lower-cost generic and biosimilar versions of drugs and biological products
H.R. 938 the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019 - eligibility for FDA approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval
H.R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019 - pay for delay; prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products
H.R.2113 Prescription Drug STAR Act - require drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers,
H.R.2296, S.1391 FAIR Drug Pricing Act - Rx pricing transparency, require manufacturers to justify price increases
H.R.2376, S.1227 Prescription Pricing for the People Act - directs the Federal Trade Commission to report to Congress on the effect of certain anticompetitive practices in the pharmaceutical supply chain
S.Res.134 - A resolution expressing the sense of the Senate that the Department of Justice should reverse its position in Texas v. United States, No. 4:18-cv-00167-O (N.D. Tex.)
H.R.1010 - To provide that the rule entitled "Short-Term, Limited Duration Insurance" shall have no force or effect
H.R.1868 - Health Care Affordability Act of 2019 - reducing insurance premiums and out-of-pocket costs in the individual and small group markets, both for low-income families and those that are not eligible for tax credits
H.R.1425 State Health Care Premium Reduction Act - Improve Health Insurance Affordability Fund to provide for certain reinsurance payments to lower premiums in the individual health insurance market
H.R.986 - Protecting Americans with Preexisting Conditions Act of 2019 - certain guidance related to waivers for State innovation under the Patient Protection and Affordable Care Act shall have no force or effect
H.R.987Strengthening Health Care and Lowering Prescription Drug Costs Ac- requires the Department of Health and Human Services (HHS) to conduct outreach and educational activities regarding federally-facilitated exchanges (i.e., health insurance exchanges that are established and operated within states by HHS). The activities must inform potential enrollees of the availability of coverage and related financial assistance under the exchanges and must be provided in culturally and linguistically appropriate formats.
S.1556No Junk Plans Act - rule entitled Short-Term, Limited Duration Insurance shall have no force or effect.
S.1531STOP Surprise Medical Bills Act - provide protections for health insurance consumers from surprise billing
H.R.861 - End Surprise Billing Act of 2019 - prevent surprise billing practices and require notification for consumers
S.1895 Lower Health Care Costs Act - comprehensive legislation to end surprise medical bills, reduce prescription drug prices, improve health care transparency, improve public health, improve exchange of health information
H.R. 3630 No Surprises Act - legislation to protect consumers from surprise medical bills, using median in network rate and an option to go to arbitration for bills above $1250.
H.R. 3502 Protecting People From Surprise Medical Bills Act - legislation to protect consumers from surprise medical bills, arbitration as payment mechanism
H.R.748, S. 684Middle Class Health Benefits Tax Repeal Act of 2019 - repeal the excise tax on high value employer-sponsored health care coverage, also known as the Cadillac Tax
S. 1801 Affordable Medications Act - increase drug price transparency and affordability, spur innovation, and enhance competition
S.455/ H.R.987 - MORE Health Education Act - funding for Federal Exchange outreach and educational activities
H.R.3180, S. 1770 RISE (Resilience Investment, Support, and Expansion) from Trauma Act - improve the identification and support of children and families who experience trauma
S.2387 We Protect American Investment in Drugs Act - prohibits Pharmaceutical companies developing prescription drugs using federally-funded research, like NIH or CDC grants, from charging American consumers unreasonable prices for life-saving drugs
H.R.2411/S.1258 Tobacco to 21 Act - prohibit the sale of tobacco products to individuals under the age of 21
H.R.2339 Reversing the Youth Tobacco Epidemic Act - legislation to curb the rise of youth tobacco use
H.R. 4548 Asthma Care and Prevention in Rural Communities Act -authorize CDC to award grants to eligible counties for the use of mobile clinics and distance learning and telemedicine to diagnose and treat children with asthma in rural areas and medically underserved communities,
H.R.4158 CURE High Drug Prices Act - prohibit price gouging in the sale of drugs
H.R.4575 - Improving Provider Directories Act - require group health plans and health insurance issuers offering group or individual health insurance coverage to establish a process to address inaccurate information listed in publicly accessible provider directories of such plans and issuers
H.R. 4457 Chronic Condition Copay Elimination Act - require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for additional preventive care for individuals with chronic conditions without the imposition of cost sharing requirement
H.R.2374 Stop STALLING Act - enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns
H.R.1983 Community Health Investment, Modernization, and Excellence Act of 2019 - reauthorize and extend funding for community health centers and the National Health Service Corp
Legislation to prevent air ambulances from balance billing patients
Legislation to require health care facilities and providers to give patients a list of services received upon discharge
Legislation to reauthorize the Patient-Centered Outcomes Research Institute (PCORI)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3 Lower Drug Costs Now Act of 2019 -allowing Medicare to negotiate prescription drug prices, limiting the ability of drug companies to spike their prices overnight, ensuring that actions to address egregious prices apply to coverage beyond Medicare
S. 2543 Prescription Drug Pricing Reduction Act of 2019 - comprehensive legislation to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers
H.R. 3853 Personal Needs Allowance Modernization Act of 2019 - increase under the Medicaid program the minimum monthly personal needs allowance for institutionalized individuals and couples
H.R.4386 Stop the Wait Act - eliminate the Medicare and disability insurance benefits waiting periods for disabled individuals.
H.R.1393 Medicare Dental, Vision, and Hearing Benefit Act of 2019 - provide for coverage of dental, vision, and hearing care under the Medicare program.
H.R.576 Seniors Have Eyes, Ears, and Teeth Act - expands Medicare coverage to include eyeglasses, hearing aids, and dental care.
S.22/H.R.2951 Medicare Dental Benefit Act of 2019 - coverage of dental services under Medicare Part B
H.R.1342 EMPOWER Care Act - reauthorize the Money Follows the Person Demonstration Program
H.R. 1343 - Protecting Married Seniors Act - provisions regarding Medicaid eligibility that protect against spousal impoverishment for recipients of home and community-based services.
S.99 / H.R.448 - The Medicare Drug Price Negotiation Act - negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D
H.R.1046 / S.377 Medicare Negotiation and Competitive Licensing Act of 2019 - requiring Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program
S.470 Medicare at 50 Act - option for any citizen or permanent resident of the United States age 50 to 64 to buy into Medicare
H.R.1329 Medicaid Reentry Act - allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release
H.R.1354 Territories Health Equity Act - make improvements to the treatment of the United States territories under the Medicare and Medicaid programs
H.R.1384, S.1129 Medicare for All Act - establishes a national health insurance program
Medicare Prescription Drug Savings and Choice Act - public option for drug coverage within Medicare Part D
HEAL for Immigrant Women and Families Act of 2019 - Removes the five year waiting period for immigrants to become eligible for Medicaid and CHIP
H.R.2463, S.1261 Choose Medicare Act - establishment of Medicare part E public health plans
S.1423Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2019 - provide for coverage of dental, vision, and hearing care under the Medicare and Medicaid programs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Fiscal Year 2020 Appropriations -
Funding for CDC's National Asthma Control Program
Funding for CDC to conduct public health research into firearm morbidity and mortality prevention
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
H.R. 1236 the Extreme Risk Protection Order Act of 2019 - authorize the issuance of an extreme risk protection order by a federal court when law enforcement, family members, or household members seek one; support State, Tribal, and local efforts to remove access to firearms from individuals who are a danger to themselves
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Sheehan |
|
|
|
Shawn |
Gremminger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |